Navigation Links
Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
Date:5/16/2013

NEW YORK, May 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target Alpha Therapy (TAT) international symposium will feature a presentation devoted to Actinium Pharmaceuticals' clinical programs.  The abstract entitled "Alpha-Particle Immunotherapy for Acute Myeloid Leukemia with Bismuth-213 and Actinium-225" has been accepted for oral presentation to be delivered by Dr. Joseph Jurcic , Chief of Leukemia Services at New York Presbyterian/Columbia.

"Alpha emitters offer the possibility of more efficient leukemia cell killing without the toxicity of intensive chemotherapy," said Dr. Jurcic.  "We are now studying this modality in combination with low-dose chemotherapy in older AML patients for whom new treatments are desperately needed.   The average age for AML patients is 68.  Most of these patients cannot tolerate intensive treatments, and their prognosis is extremely poor.  A drug like Actimab-A™ could allow them to avoid the side effects of standard chemotherapy."

Dr. Jurcic's presentation will focus on Actinium Pharmaceuticals' drug candidates Actimab-A™ and Bismab.  It will take place during the 8th Targeted Alpha Therapy (TAT) international symposium that will be held in Oak Ridge, TN.

About Actimab-A™

Actimab-A™ is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells.  Actimab-A™ consists of the Lintuzumab monoclonal antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first co-developed by Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or Contact:

Segio Traversa , CEO
Actinium Pharmaceuticals, Inc.
E-mail: actimedia@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr. , 203-258-0159
Tel:  (203) 258-0150
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
2. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
3. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
4. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
5. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
6. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
7. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
10. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
11. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):